TITLE

A Sure shot

AUTHOR(S)
Coghlan, Andy
PUB. DATE
February 2002
SOURCE
New Scientist;2/16/2002, Vol. 173 Issue 2332, p17
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Examines the development of vaccine for tuberculosis in Africa. Causes of the disease; Use of Mycobacterium bovis in the creation of the vaccine; Strains of mycobacteria.
ACCESSION #
7375038

 

Related Articles

  • The consequences of vaccination with the Johne's disease vaccine, Gudair, on diagnosis of bovine tuberculosis. Coad, M.; Clifford, D. J.; Vordermeier, H. M.; Whelan, A. O. // Veterinary Record: Journal of the British Veterinary Association;3/9/2013, Vol. 172 Issue 10, p1 

    The single intradermal comparative cervical tuberculin skin-test (SICCT) remains the primary surveillance tool to diagnose bovine tuberculosis (BTB) in the UK. Therefore, understanding the potential confounding influences on this test is important. This study investigated the effects of...

  • A second-generation anti TB vaccine is long overdue. Castañón-Arreola, Mauricio; López-Vidal, Yolanda // Annals of Clinical Microbiology & Antimicrobials;2004, Vol. 3, p10 

    Mycobacterium bovis BCG vaccine significantly reduces the risk of tuberculosis by 50% and continues to be used to prevent tuberculosis around the world. However, it has been shown to be ineffective in some geographical regions. The existence of different BCG strains was described more than 60...

  • Recombinant Mycobacterium bovis BCG as an HIV Vaccine Vector. Chapman, Rosamund; Chege, Gerald; Shephard, Enid; Stutz, Helen; Williamson, Anna-Lise // Current HIV Research;Jun2010, Vol. 8 Issue 4, p282 

    HIV-1 has resulted in a devastating AIDS pandemic. An effective HIV/AIDS vaccine that can be used to either, prevent HIV infection, control infection or prevent progression of the disease to AIDS is needed. In this review we discuss the use of Mycobacterium bovis BCG, the tuberculosis vaccine,...

  • A Mycobacterium bovis BCG-Naked DNA Prime-Boost Vaccination Strategy Induced CD4+ and CD8+ T-Cell Response against Mycobacterium tuberculosis Immunogens. Miao Lu; Zhi Yang Xia; Lang Bao // Journal of Immunology Research;2014, p1 

    Mycobacterium tuberculosis infection is still a major global public health problem. Presently the only tuberculosis (TB) vaccine available is Bacille Calmette-Guerin (BCG), although it fails to adequately protect against pulmonary TB in adults. To solve this problem, the development of a new...

  • Can the Efficacy of Bacille Calmette-Guérin Tuberculosis Vaccine Be Affected by Intestinal Parasitic Infections? Ferreira, Ana Paula; Dockrell, H.M.; Black, G.F.; Weir, R.E.; Fine, P.E.M. // Journal of Infectious Diseases;8/1/2002, Vol. 186 Issue 3, p441 

    Discusses a study which evaluated the effect of bacille Calmette-Guerin (BCG) vaccination on in vitro Mycobacterium bovis-induced cytokine production by whole blood cells from persons infected with intestinal parasites. Intestinal parasites found from 14 male students aged 12-15 in Brazil;...

  • Tuberculosis vaccine strain Mycobacterium bovis BCG Russia is a natural recA mutant. Keller, Peter M.; Böttger, Erik C.; Sander, Peter // BMC Microbiology;2008, Vol. 8, Special section p1 

    Background: The current tuberculosis vaccine is a live vaccine derived from Mycobacterium bovis and attenuated by serial in vitro passaging. All vaccine substrains in use stem from one source, strain Bacille Calmette-Guérin. However, they differ in regions of genomic deletions, antigen...

  • Antituberculars which target decaprenylphosphoryl-β-D-ribofuranose 2′-oxidase DprE1: state of art. Buroni, Silvia; Pasca, Maria; Jesus Lopes Ribeiro, Ana; Degiacomi, Giulia; Molteni, Elisabetta; Riccardi, Giovanna // Applied Microbiology & Biotechnology;May2012, Vol. 94 Issue 4, p907 

    Multidrug resistance is a major barrier in the battle against tuberculosis and still a leading cause of death worldwide. In order to fight this pathogen, two routes are practicable: vaccination or drug treatment. Vaccination against Mycobacterium tuberculosis with the current vaccine...

  • Blast from the past. Bird, Lucy // Nature Reviews Immunology;Apr2007, Vol. 7 Issue 4, p248 

    The article discusses the reducing effectiveness of the strains of the Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccine in providing protection against tuberculosis. A comparative study done by a group led by Stewart Cole of the genomes of ten strains of the BCG vaccine used between...

  • Recombinant BCG Vaccine Candidates. Hernàndez-Pando, Rogelio; Castañòn, Mauricio; Espitia, Clara; Lopez-Vidal, Yolanda // Current Molecular Medicine;Jun2007, Vol. 7 Issue 4, p365 

    Given the variable protective efficacy provided by Mycobacterium bovis BCG (Bacillus Calmette-Guerin), there is a concerted effort worldwide to develop better vaccines that could be used to reduce the burden of tuberculosis. Recombinant BCG (rBCG) are vaccine candidates that offer some potential...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics